Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients

Journal of Neurology

Volumn 260, Issue 12, 2013, Pages 3023-3029

  Takeuchi, Fumi ^a   Yonemoto, Naohiro ^a   Nakamura, Harumasa ^a   Shimizu, Reiko ^a,b   Komaki, Hirofumi ^a   Mori Yoshimura, Madoka ^a   Hayashi, Yukiko K ^a,d   Nishino, Ichizo ^a   Kawai, Mitsuru ^c   Kimura, En ^a   Takeda, Shin'Ichi ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Higashisaitama National Hospital   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Duchenne muscular dystrophy; National registry; Natural history; Prednisolone; Walking

Indexed keywords

DYSTROPHIN; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; MISSENSE MUTATION; MUSCLE BIOPSY; NEPHROTIC SYNDROME; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; WALKING;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; HUMANS; JAPAN; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISOLONE; REGISTRIES; RETROSPECTIVE STUDIES; WALKING; YOUNG ADULT;

EID: 84890638565     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7104-y     Document Type: Article

References (32)

1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, Hamil C, Mahmoud M, Roush K, Bird L, Rankin C, Lilly H, Street N, Chandrasekar R, Weiss RB (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304-313
2. Drachman DBTK, Myer E (1974) Prednisone in Duchenne muscular dystrophy. Lancet 14:1409-1412
3. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robison J, Kaiser K, Mandel S, Arfken C, Gilder B (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320:1592-1597
4. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C (1994) Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 17:386-391
5. Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A (2001) Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull 27:38-42
6. Manzur AY, Kuntzer T, Pike M, Swan A (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev: CD003725
7. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP (1991) Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 48:383-388
8. Balaban B, Matthews DJ, Clayton GH, Carry T (2005) Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy. Am J Phys Med Rehabil 84:843-850
9. Biggar WD, Harris VA, Eliasoph L, Alman B (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Disord 16:249-255
10. Houde S, Filiatrault M, Fournier A, Dube J, D'Arcy S, Berube D, Brousseau Y, Lapierre G, Vanasse M (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38:200-206
11. Straathof CS, Overweg-Plandsoen WC, van den Burg GJ, van der Kooi AJ, Verschuuren JJ, de Groot IJ (2009) Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol 256:768-773
12. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68:1607-1613
13. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S, Talim B, Ferlini A, Cicognani A, Franzoni E (2012) Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 45:796-802
14. Pradhan S, Ghosh D, Srivastava NK, Kumar A, Mittal B, Pandey CM, Singh U (2006) Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253:1309-1316
15. John R, Bach DM, Saulat B (2010) Duchenne muscular dystrophy. The effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil 89:620-624
16. Yilmaz O, Karaduman A, Topaloglu H (2004) Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol 11:541-544
17. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K (2010) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25:1116-1129
18. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, Group DMDCCW (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77-93
19. Nakamura H, Kimura E, Mori-Yoshimura M, Komaki H, Matsuda Y, Goto K, Hayashi YK, Nishino I, Takeda SI, Kawai M (2013) Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet J Rare Dis 8:60
20. Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L, Campbell C, Dai Y, Barisic N, Kos T, Brabec P, Rahbek J, Lahdetie J, Tuffery-Giraud S, Claustres M, Leturcq F, Ben Yaou R, Walter MC, Schreiber O, Karcagi V, Herczegfalvi A, Viswanathan V, Bayat F, de la Caridad Guerrero Sarmiento I, Ambrosini A, Ceradini F, Kimura E, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Oliveira J, Santos R, Neagu E, Butoianu N, Artemieva S, Rasic VM, Posada M, Palau F, Lindvall B, Bloetzer C, Karaduman AA, Topaloglu H, Inal HS, Oflazer P, Stringer A, Shatillo AV, Martin AS, Peay H, Flanigan KM, Salgado D, von Rekowski B, Lynn S, Heslop E, Gainotti S, Taruscio D, Kirschner J, Verschuuren J, Bushby K, Beroud C, Lochmuller H (2013) The TREAT-NMD Duchenne muscular dystrophy registries: conception, design and utilisation by industry and academia. Hum Mutat. doi: 10.1002/humu.22390 [Epub ahead of print]
21. John P, Klein MLM (2003) Survival analysis: techniques for censored and truncated data (statistics for biology and health). Springer, Berlin
22. Dubowitz V (1995) Muscle disorders in childhood. WB Saunders, London
23. Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig 1:1217-1235
24. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, Muntoni F, on behalf of the NorthStar Clinical N, Dubowitz Neuromuscular Centre GOSHfCNHSTL (2013) Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84(6):698-705
25. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34:135-144
26. Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731-740
27. Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C, Quality Standards Subcommittee of the American Academy of N, Practice Committee of the Child Neurology S (2005) Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64:13-20
28. Hoffman EP, Reeves E, Damsker J, Nagaraju K, McCall JM, Connor EM, Bushby K (2012) Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 23:821-828
29. Kley RA, Tarnopolsky MA, Vorgerd M (2011) Creatine for treating muscle disorders. Cochrane Database Syst Rev: CD004760
30. Davidson ZE, Truby H (2009) A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet Off J Br Diet Assoc 22:383-393
31. Beytia Mde L, Vry J, Kirschner J (2012) Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol 31:4-8
32. McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, Cnaan A, Cinrg I (2013) The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48:32-54